LQT Therapeutics

LQT Therapeutics is a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases.

LQT Therapeutics' mission is to relentlessly pursue precision therapies to treat Long QT Syndrome, allowing people to live their best lives.

LQTT was launched in 2019 at the Fonds de solidarité FTQ, by Anthony Rosenzweig, David Milan and Saumya Das. The company is headquartered in Laval , Québec, Canada.

 

LQTT is advancing a series of in-licensed compounds discovered and developed by Sanofi S.A. (Paris, France) which inhibit Serum/Glucocorticoid Regulated Kinase 1 (SGK1).

 

LQTT has successfully reproduced the positive effects of SGK1 inhibition in stem-cells of patients with Long QT Syndrome and various in vitro models of cell proliferation for prostate cancer and anticipates presenting this new data at an upcoming scientific conference.

 

LQTT is backed by Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Amzak Health, Alexandria Venture Investments, and others. The company completed a $19M Series A round on Aug 10, 2021. This brings LQTT's total funding to $20.4M to date.

 

 

 

  • Year founded: 2019
  • Funding Info: $20.4M over 2 Rounds (Latest Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 2-10
  • Business Valuation: NA
  • City/Town: Laval
  • State: Québec
  • Country: Canada
Related businesses